Nanosonics to Showcase Innovative trophon2 at ACOG 2019 Annual Meeting

HLD solution proven to reduce risk of ultrasound probe
cross-infection without harm to environment

NASHVILLE, Tenn.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/HLD?src=hash” target=”_blank”gt;#HLDlt;/agt;–Nanosonics
(ASX: NAN), a leader in infection prevention solutions, announced it
will highlight the proprietary trophon^®2
system, the latest innovation in ultrasound probe high level
disinfection (HLD) at the American College of Obstetricians and
Gynecologists (ACOG)
Annual Meeting.

Nanosonics’ trophon2 offers a complete reprocessing solution to optimize
ultrasound probe decontamination while helping to ensure compliance with
the latest guideline requirements without the use of hazardous chemicals.

“In the private office setting, it’s important for me to be able to
provide high-quality ultrasound capabilities to my patients,” said
Steven W. Tucker, M.D., FACOG, president and medical director of
Advanced Menstrual Care Center in Townson, Md. “This, coupled with my
commitment to quality and safety, necessitates that I use trophon2, as
it is the only option there is for complete patient safety and full
compliance.”

The trophon* technology’s high-frequency ultrasonic vibrations generate
a sonically activated, supercharged hydrogen peroxide (H₂O₂)
mist that inactivates an extended range of infectious pathogens that
other HLD products do not, including Sexually Transmitted Infections
(STIs), Clostridium difficile spores and drug resistant bacteria.^#
trophon is a pioneer globally in microbial efficacy, the first HLD
system in the world proven to kill native, infectious, high-risk HPV¹.

“To deliver maximum patient safety, disinfection and infection control
methods need to meet or exceed today’s demanding guidelines and
requirements,” said Peter McGovern, M.D., medical director for
University Reproductive Associates of New Jersey. “After investigating
Nanosonics’ trophon technology, we quickly realized it was the only
option available that would keep our patients safe and give us peace of
mind. There is no substitute for patient safety and security in modern
medical care.”

“We are excited to showcase our trophon2 for the first time to attendees
of ACOG 2019, and this year’s meeting focus on clinically relevant
innovations that are practice-ready couldn’t be more pertinent,” said
Ken Shaw, president of North America for Nanosonics. “Considered the new
standard of care in Ob/Gyn, trophon is recognized as the leading
automated HLD solution for transvaginal, transrectal and surface probes.
It delivers a smarter option that provides the
broadest possible microbial efficacy to dramatically reduce the risk
of cross infection from ultrasound probes.”

Nanosonics’ trophon systems are installed in more than 4,000 hospitals
and facilities in North America including all of the top 50 U.S.
hospitals** and it’s estimated that trophon technology is reducing the
risk of cross-contamination for over 60,000 patients daily. The device
is compatible for use with over 1,000 probes.

To learn more about Nanosonics’ HLD solution, please visit their booth
#2119 during ACOG 2019, May 3-6 in the Nashville Music City Center,
Nashville, Tenn.

About Nanosonics

Nanosonics
(ASX:NAN) is a leading medical technology company headquartered in
Sydney, Australia, with its North American operations based in
Indianapolis. Founded in 2001, the company is one of Australia’s largest
medical technology companies and a recognized leader in its sector of
the global infection control market. More information may be found at www.nanosonics.com.us.

*trophon [trophon EPR & trophon2]
1. Ryndock E, Robison R,
Meyers C. Susceptibility of HPV16 and 18 to high level disinfectants
indicated for semi-critical ultrasound probes. J Med Virol.
2016;88(6):1076-80.
^# Nanosonics internal test data
**US
News and World Report.

Contacts

Amy Cook
amy@amcpublicrelations.com
https://www.nanosonics.us/news/media-kit/